Health Canada has approved cladribine tablets for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS), to reduce the frequency of clinical exacerbations and delay the progression of disability. The drug, marketed as Mavenclad, may be used for newly-diagnosed patients, but is generally recommended in MS patients with an inadequate response or poor tolerability to a prior MS therapy.
Cladribine will be available as 10-mg pills, with dosing determined by body weight. The drug is administered for 4-5 days in weeks 1 and 5 in Year 1, and weeks 1 and 5 in Year 2. The cumulative dose is 3.5 mg/kg over two years.